A new meta-analysis shows that SGLT2 inhibitors, commonly used for blood sugar control, significantly lower the risk of organ rejection in diabetic patients after a heart transplant.
Researchers analyzed eight studies involving 2,755 participants. The results indicate a 15% lower rejection risk for those taking SGLT2 inhibitors (RR: 0.85). However, no significant changes were seen in mortality, kidney function, or glycemic control.
The authors suggest the drugs' pleiotropic effects may offer immunomodulatory benefits, but stress that further research is needed to assess long-term survival outcomes.